Summary The aim of the present paper was to analyse the effect of long-term inhibitory treatment, for at least 7 days, of individual protein kinase C (PKC) isoforms on the survival of LoVo human colon adenocarcinoma cells to doxorubicin exposure. The treatment for 2 h, after plating the cells, and after 3 days with 1 gM Go6976, a specific inhibitor of protein kinase C (PKC)-a and -i1 isoforms, induced on day 7 in LoVo cell lines (WT) a significant increased survival when these cells were exposed to increasing doxorubicin concentrations. In contrast. resistant LoVo cells (DX) did not show significant changes in the survival to doxorubicin exposure when incubated with the inhibitor of the same specific PKC isoforms. In addition, G66976 reduced the PKC-a activity (the main calcium-dependent PKC isoforms expressed) in both cell lines with contemporary increased expression. Under such conditions. an increased nuclear activity and an increased P-glycoprotein expression occurred only in WT-treated cells with respect to untreated cells. Taken together, our data indicate a specific relationship between PKC-a inhibition, the increased nuclear PKC-a activity as well as the increased expression of P-glycoprotein. possibly causing the acquisition of a resistant phenotype in WT LoVo cells.
Tumour cells develop drug resistance through multiple mechanisms. One form of drug resistance. termed multidrua resistance' (MDR) leads to simultaneous cross-resistance to several structurallv unrelated natural products. The mechanism 5s1 of resistance is due to an energx -dependent drug efflux w hich results in a net decreased intracellular drug accumulation. Malignant mammalian cell lines w-ith the MDR phenotype may haxe an amplified rndr-I gene or an increased protein product of the mdr-J cene called P-glycoprotein (Fine et al. 1996) . Numerous papers demonstrated that MDR xwas associated with many changes in tumour cells. including increased glutathione peroxidase actixitv. decreased levels and mutations in DNA topoisomerases. decreased lexvels of cNtochrome P450 enzymes. ox erexpression of the anionic isoenzvme of glutathione-Stransferase. an altered cell membrane composition and changes in the expression and actixity of protein kinase C (PKC) isoenzymes (Endicott and Lina. 1989: O'Brian and Ward. 1989) .
In human breast cancer cells. phorbol esters increase PKC protein lexels as well as the drug resistance in clonogenic assay (Fine et al. 19881 . A number of laboratories have reported an increased actixvitv and/or amount of PKC in MDR cell lines such as sarcoma-180 (Posada et al. 1989a) . murine fibrosarcoma (Ward and O Brian. 1991f. P-388 leukaemia (Gallapudi et al. 1992) . HL- 60 leukaemia (Aquino et al. 1988) . human KB-carcinoma cells IPosada et al. 1989b ) and murine DCF-3F cells (Palavoor et al. 1987) . In X itro. P-gl-coprotein is phosphon-lated by PKC at serine residues (Chambers et al. 1993: Orr et al. 19931 (Beck et al. 1996) .
The aim of the present study was to clarifx the role of c-PKC isoforms in the acquisition of a drug-resistant phenotype. We used as a model the well-characterized human colon adenocarcinoma LoVo cell lines sensitixe (OWT) or resistant (DX) to doxorubicin after continuous exposure to the druc. A prexious paper demonstrated that VT and DX cells express mainly the PKC-a isoform. PKC-4 show-ing an actixitv eightfold loxxwer than PKC-ot. PKC-y beinc undetectable (Dolfini et al. 1993) .
In this studv. we demonstrate that long-term inhibition of the PKC-a isoform x ith G66976. a PKC inhibitor specifically selected for ax and PI PKC isoforms IFigure 11 (Martinx-Baron et al. 1993) . treating these cells for 2 hours after plating and 3 days later induced on dax 7 in LoVo AXT cells a significant increase in surxix al x hen exposed to doxorubicin. suggesting a possible inx olxement of such isoenzy me in the acquisition of a drugresistant phenotype. The c-PKC activity was assayed 4 days later. ND = not detected. **P < 0.01 vs. untreated control.
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MATERIALS AND METHODS Cell culture
The human colon adenocarcinoma WT LoVo cell line (American Type Culture Collection, Rockville, USA) was grown in vitro in F12 medium supplemented with 10% fetal calf serum and maintained at 370C in a humid atmosphere (5% carbon dioxide-95% air). DX LoVo cells were isolated after repeated treatment of such cells with doxorubicin (Grandi et al, 1986 ).
Inhibition of PKC isoforms
Subconfluent cells were treated with 1 ,UM Go6976 (Calbiochem, La Jolla, CA, USA) for 2 h. The medium was removed and fresh medium was added for 24 h. After 3 days, the cells were treated again with 1 ,UM Go6976 for 2 h and fresh medium was added. After 4 days, the cells were detached by trypsinization (Trypsin 0.05%-EDTA 0.02%, Life Technologies) and used for subcellular fractionation or for Western blot analysis.
Clonogenic surviving test
Four hundred cells were plated in tissue culture dishes, exposed to 1 ,UM G66976 for 2 h and then treated with increasing concentrations of doxorubicin for 24 h. Medium was then removed and fresh medium was added. After 3 days, the cells were exposed again to G66976 and 4 days later the surviving colonies, grown in drug-free medium, were counted.
Subcellular fractionation and PKC assay
Particulate, cytosolic and nuclear fractions were obtained as previously described (La Porta and Comolli, 1995 (1998) 78(10) 
RESULTS
LoVo WT cells continuously exposed to doxorubicin acquire a resistant phenotype (DX), and express higher levels of mdr-l mRNA encoding for the P-glycoprotein (Grandi et al, 1986) . WT and DX LoVo cells express only PKC-a, being PKC-P and -y undetectable using Western blot analysis (data not shown) according to Beck et al. (1996) . To inhibit PKC-x for long periods, at least 7 days, an experimental protocol was considered. We tested different concentrations of Go6976 and we used the lowerst concentration able to inhibit significantly PKC-a activity (data not shown). Moreover, with the purpose of reducing the toxicity of the Go6976 and also of maintaining the PKC-a isoform inhibited for long British Joumal of Cancer (1998) 78(10) periods. Under such conditions. XXT cells receiving, the complete inhibitors treatment and exposed to increasina concentrations of doxorubicin (from 20 ng ml-' to 50 ng ml ') show-ed an enhanced cell survixal w%ith respect to untreated cells (Figure 4) . In fact. in spite of the slight inhibition of the proliferative capacity in both cell lines (Figure 2) . LoVo WT cells treated with the selectixe inhibitor Go6976 w ere susceptible to a higher doxorubicin concentration (80 ng ml-'). Moreover. WT-treated cells showed an increased P-glycoprotein expression ( Figure 5 ). In contrast. DX cells treated with the PKC inhibitor did not showv significant changes with respect to untreated cells in the sunrixal of doxorubicin exposure (Figure 4) . and the lexel of P-glvcoprotein did not show anv significant chance (data not shown).
We also analvsed the nuclear actix itv and expression of PKC-ax. the main PKC isoform expressed in these cells. in both cell lines untreated or treated w-ith G66976. WT-treated cells showed a sirnificant increase (P<0.01) of nuclear PKC-ot actixitx with respect to untreated cells ( Figure 6 ) w-ithout changes in its expression (Figure 7) . In contrast. no significant nuclear activity and expression was detected in untreated DX cells (Figure 7) . DISCUSSION P-gl coprotein expression is commonl-obser-ed in MDR cell lines. including LoVo DX cells (Grandi et al. 1986 (PMA) or diacylglycerol increased the level of both mdr-J and P-glycoprotein (Gupta et al. 1994) . In greneral. PKC-at appears One hundred micrograms of protein was subnmitted to 100o SDS-PAGE and then transferred to nitrocellulose sheet ovemight. The sheet was incubated with 2.5 pg mrn, anti-PKC-a antibody. Peptide used to raise the anti-PKC antibody was used in competition studies to demonstrate the specficty of the polycdonal antibody. Nuclear fraction obtained from brain tissue was used as positive control the most consistently implicated isoform. In fact. increased expression of such isoenzymes has been reported in a number of cell lines selected for resistance to sexeral anti-cancer agents. includinc doxorubicin-resistant MCF-7 breast carcinoma cells (Blobe et al. 1993 ). doxorubicin-. vinblastine-and colchicineresistant KB human epidermoid carcinoma cells (Davies et al. 1996) and in KB-A 10 cell lines (Posada et al. 1989b) .
In this report. we has-e studied the effect of long-term inhibition of the PKC-a isoform on the survival of WT and DX LoVo cells to increasing concentrations of doxorubicin. Treatment Ax ith the specific PKC-oa and [I isoforms inhibitor. G66976 (MartinsBaron et al. 1993) . inhibited PKC-c activitv. the main PKC isoform expressed in such cells (Drewx et al. 1994 Inhibibon of PKC-a affects LoVo survival to doxorubicin 1287 probably maintained the drug resistant state of these cells (Lee et al. 1992) . In contrast. in DX cell lines we did not find any significant expression of such isoforms in the nucleus. c-PKC-a showing a different subcellular distribution in DX LoVo with respect to MCF-7 cell lines. Recently. other specific PKC inhibitors such as bisindolylmaleimide and calphostin C blocked the activation of NF-kB. suggesting a relationship between PKC activation and NFkB activation that might contribute to the expression of genes involved in the resistant phenotype (Das and White. 1997 ). In addition. the modulation of other kinases downstream with respect to PKC-a might be involved in the acquisition of the resistant phenotype of LoVo WT cells.
Taken together. our results indicate a relationship between PKCa inhibition. an increased nuclear activity of this isoform and the acquisition of a resistant phenotype in LoVo WT cells. It is tempting to speculate that overexpression of c-PKC-oa and the long-term inhibition of such isoforms induce a resistant phenotype possibly through different mechanisms. In the first case. the permanent high level of c-PKC-a is likely to induce the phosphorylation of P-glycoprotein. whereas in the second case the long-term inhibition enhances the P-glycoprotein level. Therefore. the hypothesis speculated by several authors that the selective inhibition of PKC-a may chemosensitize tumour cefls to anti-cancer therapy might not be correct. Recently. different concentrations of doxorubicin induced apoptosis or oxidative DNA damage (Muller et al. 1997) . Work is in progress to analyse the intracellular role of PKC-a with respect to the cytotoxic mechanism of doxorubicin under the present conditions and also in other human cell lines.
